TrialLong-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Trial details
- Registry ID
- NCT03179631
- Phase
- Phase 3
Drug research
Ataluren
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as PTC124; Translarna
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyNCT03179631 | PTC Therapeutics | Phase 3 | Completed | 2022-03-05Actual |
| A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)NCT04336826 | PTC Therapeutics | Phase 2 | Completed | 2023-08-07Actual |
| Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)NCT01247207 | PTC Therapeutics | Phase 3 | Completed | 2026-02-10Actual |
A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Trial details
- Registry ID
- NCT04336826
- Phase
- Phase 2
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Trial details
- Registry ID
- NCT01247207
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |